{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T10:52:54Z","timestamp":1786272774932,"version":"build-2736575974"},"reference-count":143,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T00:00:00Z","timestamp":1590624000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Muscle and Nerve"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>With the exception of thymectomy, immune modulatory treatment strategies and clinical trials in myasthenia gravis over the past 50 y were mainly borrowed from experience in other nonneurologic autoimmune disorders. The current experimental therapy paradigm has significantly changed such that treatments directed against the pathological mechanisms specific to myasthenia gravis are being tested, in some cases as the initial disease indication. Key advances have been made in three areas: (i) the expanded role and long\u2010term benefits of thymectomy, (ii) complement inhibition to prevent antibody\u2010mediated postsynaptic membrane damage, and (iii) neonatal Fc receptor (FcRn) inhibition as in vivo apheresis, removing pathogenic antibodies. Herein, we discuss these advances and the potential for these newer therapies to significantly influence the current treatment paradigms. While these therapies provide exciting new options with rapid efficacy, there are anticipated challenges to their use, especially in terms of a dramatic increase in cost of care for some patients with myasthenia gravis.<\/jats:p>","DOI":"10.1002\/mus.26919","type":"journal-article","created":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T07:48:56Z","timestamp":1590652136000},"page":"579-592","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Update on immune\u2010mediated therapies for myasthenia gravis"],"prefix":"10.1002","volume":"62","author":[{"given":"Ali Aamer","family":"Habib","sequence":"first","affiliation":[{"name":"Department of Neurology University of California Irvine California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghazaleh","family":"Ahmadi Jazi","sequence":"additional","affiliation":[{"name":"Department of Neurology University of California Irvine California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahseen","family":"Mozaffar","sequence":"additional","affiliation":[{"name":"Department of Neurology University of California Irvine California"},{"name":"Department of Orthopedic Surgery University of California Irvine California"},{"name":"Departments of Pathology and Laboratory Medicine University of California Irvine California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,5,28]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2005.08.007"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI29894"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002790"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.2009.00684.x"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2014.17"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.5152\/eurasianjmed.2017.17009"},{"key":"e_1_2_8_8_1","unstructured":"Medscape. Myasthenia gravis treatment & management. Approach considerations. Pharmacologic therapy. Management of neonatal myasthenia gravis. September2018.https:\/\/emedicine.medscape.com\/article\/1171206-treatment#showall. Accessed December 9 2018."},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602489"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0875-9"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26447"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.5125"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007600"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.1.7"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-018-0837-z"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(77)92118-3"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410220205"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2014.971757"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.22103"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5223(03)00938-3"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.22006"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000150587.71497.B6"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20386"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.03.004"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26404"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199406233302507"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419832242"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.21037\/acs.2019.02.04"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezu309"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00383-017-4086-3"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-017-3058-7"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1988.tb06970.x"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.62.2.156"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2011.08.001"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.48.4.332"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1067\/mtc.2001.116191"},{"issue":"2","key":"e_1_2_8_37_1","first-page":"313","article-title":"The result of extended thymectomy in patients with myasthenia gravis of pure ocular type","volume":"37","author":"Yang DS","year":"1989","journal-title":"Nihon Kyobu Geka Gakkai Zasshi."},{"issue":"12","key":"e_1_2_8_38_1","first-page":"1017","article-title":"Effect of extended thymectomy in myasthenia gravis of pure ocular type","volume":"46","author":"Kodama H","year":"1993","journal-title":"Kyobu Geka."},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2012.12.053"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2018.01.003"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2016.08.008"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2003.09.016"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-198707000-00013"},{"key":"e_1_2_8_44_1","first-page":"CD005081","article-title":"Medical and surgical treatment for ocular myasthenia","volume":"2","author":"Benatar M","year":"2006","journal-title":"Cochrane Database Syst Rev."},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12359"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30392-2"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.8206.1"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.03.003"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2016.44"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1586\/eci.12.34"},{"issue":"5","key":"e_1_2_8_51_1","first-page":"267","article-title":"Immune complexes (IgG and C3) at the motor end\u2010plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations","volume":"52","author":"Engel AG","year":"1977","journal-title":"Mayo Clin Proc."},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.6.1167"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2011.05.006"},{"issue":"8","key":"e_1_2_8_54_1","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.4049\/jimmunol.140.8.2589","article-title":"C5 gene influences the development of murine myasthenia gravis","volume":"140","author":"Christadoss P","year":"1988","journal-title":"J Immunol."},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.7.3847"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2006.06.003"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.3181\/00379727-105-26050"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2004.08.002"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21398"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.147.4.973"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21536"},{"key":"e_1_2_8_62_1","unstructured":"Soliris 300 product information.https:\/\/www.ema.europa.eu\/documents\/product-information\/soliris-epar-product-information_en.pdf. Accessed December 12 2018."},{"key":"e_1_2_8_63_1","unstructured":"Alexion Pharmaceuticals Inc. Eculizumab for use in AChR+ gMG.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125166s422lbl.pdf. Accessed October 28 2018."},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-5890(96)00078-8"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6627e1"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12347"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23839"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30369-1"},{"key":"e_1_2_8_69_1","unstructured":"Alexion Pharmaceuticals Inc. Soliris\u00ae (Eculizumab) receives marketing authorization in Japan for the treatment of patients with generalized myasthenia gravis (gMG).https:\/\/news.alexion.com\/press-release\/product-news\/soliris-eculizumab-receives-marketing-authorization-japan-treatment-patie. Accessed November 21 2019."},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-019-02148-2"},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195909"},{"key":"e_1_2_8_72_1","unstructured":"US Food and Drug Administration. FDA approves ravulizumab\u2010cwvz for paroxysmal nocturnal hemoglobinuria.FDA.2019.http:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ravulizumab-cwvz-paroxysmal-nocturnal-hemoglobinuria. Accessed September 16 2019."},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.939.939"},{"key":"e_1_2_8_74_1","unstructured":"Transforming Complement Therapeutics.https:\/\/rapharma.com\/wp\u2010content\/uploads\/2019\/07\/Ra\u2010Pharma\u2010July\u20102019\u2010Corporate\u2010Presentation.pdf. Accessed July 2019."},{"key":"e_1_2_8_75_1","unstructured":"BioPharma Global. Ra Pharmaceuticals receives orphan drug designation from the U.S. FDA for RA101495 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria.2017.https:\/\/www.biopharmaglobal.com\/2017\/08\/06\/ra-pharmaceuticals-receives-orphan-drug-designation-u-s-fda-ra101495-treatment-paroxysmal-nocturnal-hemoglobinuria\/. Accessed April 4 2019."},{"key":"e_1_2_8_76_1","unstructured":"Myasthenia Gravis News. FDA grants orphan drug status to Ra Pharma's Zilucoplan as potential MG treatment.2019.https:\/\/myastheniagravisnews.com\/2019\/09\/05\/fda-grants-orphan-drug-status-to-ra-pharmas-zilucoplan-for-mg\/. Accessed November 22 2019."},{"key":"e_1_2_8_77_1","doi-asserted-by":"publisher","DOI":"10.1038\/337184a0"},{"key":"e_1_2_8_78_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.7.3528"},{"key":"e_1_2_8_79_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2155"},{"key":"e_1_2_8_80_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830150718"},{"key":"e_1_2_8_81_1","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.71.2.666"},{"key":"e_1_2_8_82_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97911"},{"key":"e_1_2_8_83_1","first-page":"1111","article-title":"Generation and characterization of a high affinity anti\u2010human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration","volume":"10","author":"Smith B","year":"2018","journal-title":"MAbs."},{"key":"e_1_2_8_84_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.4.2.19397"},{"key":"e_1_2_8_85_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00176"},{"key":"e_1_2_8_86_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0708960105"},{"key":"e_1_2_8_87_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan1208"},{"key":"e_1_2_8_88_1","doi-asserted-by":"crossref","unstructured":"BrilV BenatarM BrockM et al. Proof\u2010of\u2010concept and safety of the Anti\u2010FcRn antibody rozanolixizumab in patients with moderate\u2010to\u2010severe generalized myasthenia gravis (GMG): a phase 2a study (S43.001) | Neurology.https:\/\/n.neurology.org\/content\/92\/15_Supplement\/S43.001. Accessed November 22 2019.","DOI":"10.1212\/WNL.92.15_supplement.S43.001"},{"key":"e_1_2_8_89_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1276"},{"key":"e_1_2_8_90_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2005.02834.x"},{"key":"e_1_2_8_91_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000256698.69121.45"},{"key":"e_1_2_8_92_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2012.06767.x"},{"key":"e_1_2_8_93_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31821e5505"},{"key":"e_1_2_8_94_1","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2016.1155452"},{"key":"e_1_2_8_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2008.07.002"},{"key":"e_1_2_8_96_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756285616641583"},{"key":"e_1_2_8_97_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25409"},{"key":"e_1_2_8_98_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.62.11.1689"},{"key":"e_1_2_8_99_1","first-page":"CD002277","article-title":"Intravenous immunoglobulin for myasthenia gravis","volume":"12","author":"Gajdos P","year":"2012","journal-title":"Cochrane Database Syst Rev."},{"key":"e_1_2_8_100_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004365"},{"key":"e_1_2_8_101_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006678312925"},{"key":"e_1_2_8_102_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.79.1.48"},{"key":"e_1_2_8_103_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-012-9720-1"},{"key":"e_1_2_8_104_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0159993"},{"issue":"15","key":"e_1_2_8_105_1","article-title":"Subcutaneous immunoglobulin in myasthenia gravis: results of a North American open label study (N4.002)","volume":"92","author":"Dimachkie M","year":"2019","journal-title":"Neurology"},{"key":"e_1_2_8_106_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.62.2.258"},{"key":"e_1_2_8_107_1","unstructured":"US Food and Drug Administration. Rituxan prescribing information.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/103705s5450lbl.pdf. Accessed November 22 2019."},{"key":"e_1_2_8_108_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20169"},{"key":"e_1_2_8_109_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar1007"},{"key":"e_1_2_8_110_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/40.2.205"},{"key":"e_1_2_8_111_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.10.883"},{"key":"e_1_2_8_112_1","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0b013e32833c0982"},{"key":"e_1_2_8_113_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncpneuro0526"},{"key":"e_1_2_8_114_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2008.02399.x"},{"key":"e_1_2_8_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2008.04.039"},{"key":"e_1_2_8_116_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2010.220475"},{"key":"e_1_2_8_117_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182407982"},{"key":"e_1_2_8_118_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25597"},{"key":"e_1_2_8_119_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004341"},{"key":"e_1_2_8_120_1","unstructured":"CuraVac. Myasterix.http:\/\/www.curavac.com\/myasterix\/. Accessed April 4 2019."},{"key":"e_1_2_8_121_1","doi-asserted-by":"publisher","DOI":"10.1006\/immu.1994.1047"},{"key":"e_1_2_8_122_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.18.8747"},{"key":"e_1_2_8_123_1","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.14.1.185"},{"key":"e_1_2_8_124_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2006.10.001"},{"key":"e_1_2_8_125_1","unstructured":"CORDISEuropean Commission. Final report summary \u2010 MYASTERIX (clinical safety immunogenicity and efficacy of a therapeutic vaccine that combines peptides mimicking antigen receptors on autoimmune B and T cells associated with myasthenia gravis).https:\/\/cordis.europa.eu\/project\/rcn\/110173\/reporting\/en. Accessed November 22 2019."},{"key":"e_1_2_8_126_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13377"},{"key":"e_1_2_8_127_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.11.6893"},{"key":"e_1_2_8_128_1","unstructured":"American College of Rheumatology. The novel anti\u2010CD40 monoclonal antibody CFZ533 shows beneficial effects in patients with primary Sj\u00f6gren's Syndrome: a phase IIa double\u2010blind placebo\u2010controlled randomized trial.https:\/\/acrabstracts.org\/abstract\/the-novel-anti-cd40-monoclonal-antibody-cfz533-shows-beneficial-effects-in-patients-with-primary-sjogrens-syndrome-a-phase-iia-double-blind-placebo-controlled-randomized-trial\/. Accessed April 4 2019."},{"key":"e_1_2_8_129_1","unstructured":"Novartis Pharmaceuticals. displaypdf.pdf.https:\/\/www.novctrd.com\/CtrdWeb\/displaypdf.nov?trialresultid=17276. Accessed April 14 2019."},{"key":"e_1_2_8_130_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcibr1006936"},{"key":"e_1_2_8_131_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2006.04.006"},{"key":"e_1_2_8_132_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756285617749134"},{"key":"e_1_2_8_133_1","unstructured":"GSK. GSK receives FDA approval for a new self\u2010injectable formulation of Benlysta (belimumab) for systemic lupus erythematosus.https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-receives-fda-approval-for-a-new-self-injectable-formulation-of-benlysta-belimumab-for-systemic-lupus-erythematosus\/. Accessed April 11 2019."},{"key":"e_1_2_8_134_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2012.06842.x"},{"key":"e_1_2_8_135_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2008.05.010"},{"key":"e_1_2_8_136_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-011-6092-z"},{"key":"e_1_2_8_137_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005323"},{"key":"e_1_2_8_138_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-015-7944-8"},{"key":"e_1_2_8_139_1","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.13503"},{"key":"e_1_2_8_140_1","doi-asserted-by":"publisher","DOI":"10.1111\/cen3.12180"},{"key":"e_1_2_8_141_1","doi-asserted-by":"publisher","DOI":"10.1159\/000322497"},{"key":"e_1_2_8_142_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25397"},{"key":"e_1_2_8_143_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000312374.95186.cc"},{"key":"e_1_2_8_144_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002795"}],"container-title":["Muscle &amp; Nerve"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmus.26919","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mus.26919","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/mus.26919","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mus.26919","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T15:09:11Z","timestamp":1722956951000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mus.26919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,28]]},"references-count":143,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1002\/mus.26919"],"URL":"https:\/\/doi.org\/10.1002\/mus.26919","archive":["Portico"],"relation":{},"ISSN":["0148-639X","1097-4598"],"issn-type":[{"value":"0148-639X","type":"print"},{"value":"1097-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,28]]},"assertion":[{"value":"2019-04-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}